🇺🇸 FDA

Intelligence · Clinical Pipeline

HOFFMANN-LA ROCHE Pipeline

All ClinicalTrials.gov programs at HOFFMANN-LA ROCHE — phase, modality, and trial IDs.

Programs
286

Quick answer

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. RO7247669

    Hoffmann-La Roche

    Melanoma

    phase 2 small molecule completed

    1 trial

  2. RO7247669

    Hoffmann-La Roche

    Unresectable or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  3. RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  4. RO7790118, RO7791094, RO7790118, Tiragolumab, Avastin 25 mg/ml concentrate for solution for infusion., RO7247669, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, ADG126, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  5. RO7790121 Placebo, RO7790121

    Hoffmann-La Roche

    Moderate to Severe Atopic Dermatitis (AD)

    phase 2 small molecule active

    1 trial

  6. RO7790121 placebo, RO7790121

    Hoffmann-La Roche

    Moderate to Severe Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  7. RO7790121, RO7790121 placebo/diluent

    Hoffmann-La Roche

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  8. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  9. RoActemra 20 mg/mL concentrate for solution for infusion, CD19 4-1 BBL, Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  10. RoActemra 20 mg/mL concentrate for solution for infusion, Glofitamab

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  11. Rozlytrek 200 mg hard capsules

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    phase 2 small molecule active

    1 trial

  12. Rozlytrek, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  13. Rybelsus 9 mg tablets, Rybelsus 1.5 mg tablets, Rybelsus 4 mg tablets, RO7795081, Rybelsus 7 mg tablets, RO7795081, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets, RO7795081, oral GLP-1R agonist (CT-996) Capsule, hard 0 mg / 1 EA - F10

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2D)

    phase 2 small molecule active

    1 trial

  14. Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  16. Tiragolumab

    Hoffmann-La Roche

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  17. Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  18. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  19. Trontinemab, Placebo Trontinemab, Flortaucipir F18

    Hoffmann-La Roche

    Alzheimer's disease

    phase 2 small molecule active

    1 trial

  20. bevacizumab [Avastin]

    Hoffmann-La Roche

    Liver Cancer

    phase 2 small molecule completed

    1 trial

  21. erlotinib [Tarceva]

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  22. A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced solid tumors

    phase 1 other active

    1 trial

  23. A SINGLE-CENTER, OPEN-LABEL, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE ITRACONAZOLE, A STRONG CYP3A INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE 30 MG DOSE OF RO7269162 IN HEALTHY PARTICIPANTS

    Hoffmann-La Roche

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  24. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)

    Hoffmann-La Roche

    Metastatic Colorectal Cancer

    phase 1 other active

    1 trial

  25. A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma

    Hoffmann-La Roche

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  26. A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

    Hoffmann-La Roche

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  27. A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

    Hoffmann-La Roche

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  28. A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)

    Hoffmann-La Roche

    Huntington’s Disease Gene Expansion Carriers

    phase 1 other active

    1 trial

  29. A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/or Metastatic Solid Tumors

    Hoffmann-La Roche

    Solid Tumors

    phase 1 other active

    1 trial

  30. A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma

    Hoffmann-La Roche

    Moderate to Severe Asthma

    phase 1 other active

    1 trial

  31. A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

    Hoffmann-La Roche

    BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases

    phase 1 other active

    1 trial

  32. A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2DM) and overweight or obesity

    phase 1 other active

    1 trial

  33. A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656, an Antisense Inhibitor of Complement Factor B

    Hoffmann-La Roche

    Hepatic Impairment

    phase 1 other active

    1 trial

  34. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Hoffmann-La Roche

    Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  35. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)

    phase 1 other active

    1 trial

  36. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  37. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Inavolisib in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  38. A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  39. A Study to Investigate the Effect of RO7504109 on Immune Cells in Healthy Participants

    Hoffmann-La Roche

    Not Applicable (N/A)

    phase 1 other active

    1 trial

  40. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  41. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  42. A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Hoffmann-La Roche

    Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)

    phase 1 other active

    1 trial

  43. A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  44. A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced Solid Tumors Harboring RAS Mutation(S)

    phase 1 other active

    1 trial

  45. A Study to find out the safety, tolerability and interaction of drug with body (including the effect of Itraconazole on RO7268489) and also what the body does to RO7268489 after oral intake by healthy participants

    Hoffmann-La Roche

    Not applicable

    phase 1 other active

    1 trial

  46. A Study to see how safe is RO7567132 as Single Agent and in Combination with Atezolizumab, how the body gets rid of it and how effective it is in people with Advanced and/or Metastatic Solid Tumors

    Hoffmann-La Roche

    Advanced and/or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  47. A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

    Hoffmann-La Roche

    HER2-positive advanced solid tumours

    phase 1 other active

    1 trial

  48. A study comparing different RO7269162 capsules and investigating the effect of food on the uptake, breakdown, and elimination of RO7269162 in Healthy Participants

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.